Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

bluebird bio Company Profile (NASDAQ:BLUE)

Consensus Ratings for bluebird bio (NASDAQ:BLUE) (?)
Ratings Breakdown: 1 Sell Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $38.93 (92.32% upside)

Analysts' Ratings History for bluebird bio (NASDAQ:BLUE)
Show:
DateFirmActionRatingPrice TargetDetailsShare
3/10/2014ZacksDowngradeNeutral -> Underperform$24.70ViewTweet This Rating  Share This Rating on StockTwits
7/30/2013Cowen and CompanyInitiated CoverageOutperform$44.00ViewTweet This Rating  Share This Rating on StockTwits
7/15/2013WedbushInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
7/15/2013JPMorgan Chase & Co.Initiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
7/15/2013Canaccord GenuityInitiated CoverageBuy$45.00ViewTweet This Rating  Share This Rating on StockTwits
7/15/2013JPMorgan Chase & Co.Initiated CoverageOverweight$44.00ViewTweet This Rating  Share This Rating on StockTwits
7/15/2013Bank of AmericaInitiated CoverageBuy$42.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 4/24/2012 forward)